Active Ingredient History
Denosumab is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alveolar Bone Loss (Phase 4)
Anesthesia (Phase 4)
Anesthesia, Local (Phase 4)
Anorexia (Phase 1)
Anorexia Nervosa (Phase 3)
Aortic Stenosis, Subvalvular (Phase 2)
Arthralgia (Phase 4)
Arthritis (Phase 1/Phase 2)
Arthritis, Juvenile (Phase 1/Phase 2)
Arthritis, Rheumatoid (Phase 4)
Arthroplasty, Replacement, Hip (Phase 1)
Bariatric Surgery (Phase 4)
beta-Thalassemia (Phase 3)
Bone Cysts, Aneurysmal (Phase 2)
Bone Density (Phase 4)
Bone Diseases (Phase 4)
Bone Diseases, Metabolic (Phase 4)
Bone Marrow Diseases (Phase 4)
Bone Marrow Transplantation (Phase 1)
Bone Neoplasms (Phase 3)
Bone Resorption (Phase 4)
BRCA1 Protein (Phase 3)
Breast Density (Phase 1)
Breast Diseases (Phase 3)
Breast Neoplasms (Phase 4)
Carcinoma (Phase 3)
Carcinoma, Giant Cell (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Renal Cell (Phase 3)
Carcinoma, Transitional Cell (Phase 2)
Cataract (Phase 3)
Charcot-Marie-Tooth Disease (Phase 3)
Chondroblastoma (Phase 2)
Chronic Periodontitis (Phase 3)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
Conscious Sedation (Phase 3)
Critical Illness (Phase 2)
Crohn Disease (Phase 1/Phase 2)
Cystic Fibrosis (Phase 4)
Dental Implantation (Phase 4)
Dermatomyositis (Phase 1/Phase 2)
Diabetes Mellitus (Phase 3)
Diabetes Mellitus, Type 2 (Phase 4)
Dialysis (Phase 4)
Drugs, Investigational (Phase 3)
Endocrine Gland Neoplasms (Phase 2)
Feeding and Eating Disorders (Early Phase 1)
Fibroma (Phase 2)
Fractures, Bone (Phase 4)
Fractures, Spontaneous (Phase 1/Phase 2)
General Surgery (Phase 2)
Giant Cell Tumor of Bone (Phase 4)
Giant Cell Tumors (Phase 2)
Gingivitis (Phase 1/Phase 2)
Gout (Phase 2)
Granuloma, Giant Cell (Phase 2)
Head and Neck Neoplasms (Phase 2)
Healthy Volunteers (Phase 1)
Hematologic Neoplasms (Phase 3)
Hematopoietic Stem Cell Transplantation (Phase 2)
Histiocytosis, Langerhans-Cell (Phase 2)
Hodgkin Disease (Phase 2)
Hyperparathyroidism, Primary (Phase 4)
Hyperplasia (Phase 3)
Hypersensitivity, Delayed (Phase 1)
Immunosuppression Therapy (Phase 1)
Infertility (Phase 2)
Infertility, Male (Phase 2)
Inflammatory Breast Neoplasms (Phase 2)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 1)
Kidney Neoplasms (Phase 2)
Kidney Transplantation (Phase 3)
Lung Neoplasms (Phase 2)
Lupus Erythematosus, Systemic (Phase 2)
Lymphoma (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Mastocytosis, Systemic (Phase 3)
Melanoma (Phase 2)
Mobility Limitation (Phase 2)
Multiple Myeloma (Phase 3)
Myositis (Phase 3)
Nasopharyngeal Carcinoma (Phase 2)
Neoplasm Metastasis (Phase 4)
Neoplasms (Phase 4)
Osteoarthritis (Phase 2)
Osteoarthritis, Hip (Phase 4)
Osteoblastoma (Phase 2)
Osteogenesis Imperfecta (Phase 3)
Osteolysis (Phase 2)
Osteoporosis ()
Osteoporosis, Postmenopausal (Phase 4)
Osteoporotic Fractures (Phase 4)
Osteosarcoma (Phase 2)
Ovarian Neoplasms (Phase 1)
Pain (Phase 2)
Parathyroid Neoplasms (Phase 3)
Pharmacokinetics (Phase 1)
Postmenopause (Phase 1)
Prostatic Neoplasms (Phase 4)
Quality of Life (Phase 4)
Renal Insufficiency, Chronic (Phase 3)
Smoldering Multiple Myeloma (Phase 2)
Spermatozoa (Phase 2)
Spinal Cord Injuries (Phase 4)
Spinal Injuries (Phase 4)
Testis (Phase 2)
Thyroid Neoplasms (Phase 2)
Ultraviolet Rays (Phase 1)
Ureteral Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Vasculitis (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
